SCHEMBL16112487

SCHEMBL16112487

CC(=O)Nc1ncc(CN2CCC(CCc3ccccc3)CC2)s1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ OGA O60502 19/20 0.69
▸ HTT P42858 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16112851 0.90 OGA (0.72) OGAHTTSMN1; SMN2
SCHEMBL16113559 0.83 OGA (0.80) OGAHTTSMN1; SMN2
SCHEMBL27022520 0.82 OGA (1.00) OGAHTTSMN1; SMN2
SCHEMBL22412795 0.81 OGA (0.63) OGA
SCHEMBL16113123 0.81 OGA (0.60) OGA
SCHEMBL16113644 0.81 OGA (0.61) OGA
SCHEMBL16114041 0.80 OGA (0.68) OGAHTTSMN1; SMN2
SCHEMBL16112504 0.80 OGA (0.70) OGA
SCHEMBL27008584 0.80 OGA (1.00) OGAHTTSMN1; SMN2
SCHEMBL20586843 0.80 OGA (0.67) OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10301299-B2 Glycosidase inhibitors MERCK PATENT GMBH (DE) 2019-05-28 — — US disclosed
US-20180093977-A1 Glycosidase Inhibitors MERCK PATENT GMBH (DE) 2018-04-05 — — US disclosed
US-20180093977-A1 Glycosidase Inhibitors MERCK PATENT GMBH (DE) 2018-04-05 — — US disclosed
US-20180093977-A1 Glycosidase Inhibitors MERCK PATENT GMBH (DE) 2018-04-05 — — US disclosed
US-9879001-B2 Glycosidase inhibitors MERCK PATENT GMBH (DE) 2018-01-30 — — US disclosed
US-9879001-B2 Glycosidase inhibitors MERCK PATENT GMBH (DE) 2018-01-30 — — US disclosed
US-9879001-B2 Glycosidase inhibitors MERCK PATENT GMBH (DE) 2018-01-30 — — US disclosed
US-20160031871-A1 Glycosidase Inhibitors YU HENRY (US) 2016-02-04 — — US disclosed
US-20160031871-A1 Glycosidase Inhibitors YU HENRY (US) 2016-02-04 — — US disclosed
US-20160031871-A1 Glycosidase Inhibitors YU HENRY (US) 2016-02-04 — — US disclosed
EP-2970272-A1 GLYCOSIDASE INHIBITORS Merck Patent GmbH (DE) 2016-01-20 — — EP disclosed
WO-2014159234-A1 GLYCOSIDASE INHIBITORS MERCK PATENT GMBH (DE) 2014-10-02 — — WO disclosed
WO-2014159234-A1 GLYCOSIDASE INHIBITORS MERCK PATENT GMBH (DE) 2014-10-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031871-A1 Glycosidase Inhibitors GAA, BACE1, GBA3 OGA 127/4885HTT 1009/4885SMN1; SMN2 1348/4885
US-10301299-B2 Glycosidase inhibitors GAA, BACE1, GBA3 OGA 127/4885HTT 1009/4885SMN1; SMN2 1348/4885
US-20180093977-A1 Glycosidase Inhibitors GAA, BACE1, GBA3 OGA 127/4885HTT 1009/4885SMN1; SMN2 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback